OCEANIC-AF and the inferior efficacy of asundexian compared to apixaban in patients at high risk with atrial fibrillation: Have we come to the end of the road for factor XIa inhibitors?
作者信息
Ferdinand Keith C, Nakhle Asaad
机构信息
Tulane University School of Medicine, Section of Cardiology, 1430 Tulane Ave, New Orleans, LA 70112, United States of America.
出版信息
Am Heart J Plus. 2024 Sep 21;46:100464. doi: 10.1016/j.ahjo.2024.100464. eCollection 2024 Oct.
Abstract
摘要
相似文献
1
OCEANIC-AF and the inferior efficacy of asundexian compared to apixaban in patients at high risk with atrial fibrillation: Have we come to the end of the road for factor XIa inhibitors?
Am Heart J Plus. 2024 Sep 21;46:100464. doi: 10.1016/j.ahjo.2024.100464. eCollection 2024 Oct.
2
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.
Lancet. 2022 Apr 9;399(10333):1383-1390. doi: 10.1016/S0140-6736(22)00456-1. Epub 2022 Apr 3.
3
What is the Future Position of Factor XIa Inhibitors for Patients with Atrial Fibrillation?
Eur Cardiol. 2024 Jul 1;19:e10. doi: 10.15420/ecr.2023.50. eCollection 2024.
4
Exploring the therapeutic utility of the factor XIa inhibitor asundexian.
Am J Health Syst Pharm. 2024 Dec 5;81(24):1222-1229. doi: 10.1093/ajhp/zxae182.
5
Asundexian versus Apixaban in Patients with Atrial Fibrillation.
N Engl J Med. 2025 Jan 2;392(1):23-32. doi: 10.1056/NEJMoa2407105. Epub 2024 Sep 1.
6
Asundexian: an oral small molecule factor XIa inhibitor for the treatment of thrombotic disorders.
Future Cardiol. 2023 Aug;19(10):477-486. doi: 10.2217/fca-2023-0051. Epub 2023 Oct 13.
7
A pharmacokinetic and pharmacodynamic evaluation of asundexian: a novel factor XIa inhibitor for stroke prevention.
Expert Opin Drug Metab Toxicol. 2024 Nov-Dec;20(11-12):1003-1011. doi: 10.1080/17425255.2024.2402496. Epub 2024 Oct 7.
8
Bleeding Outcomes in Patients Treated With Asundexian in Phase II Trials.
J Am Coll Cardiol. 2024 Feb 13;83(6):669-678. doi: 10.1016/j.jacc.2023.12.004.
9
Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and design.
Am Heart J. 2024 Nov;277:145-158. doi: 10.1016/j.ahj.2024.08.011. Epub 2024 Aug 29.
10
A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction.
Circulation. 2022 Oct 18;146(16):1196-1206. doi: 10.1161/CIRCULATIONAHA.122.061612. Epub 2022 Aug 27.
引用本文的文献
1
Factor XI and XII inhibitors-Dawn of a new era.
Indian Heart J. 2025 Mar-Apr;77(2):122-129. doi: 10.1016/j.ihj.2025.02.007. Epub 2025 Feb 25.
本文引用的文献
1
Asundexian versus Apixaban in Patients with Atrial Fibrillation.
N Engl J Med. 2025 Jan 2;392(1):23-32. doi: 10.1056/NEJMoa2407105. Epub 2024 Sep 1.
2
Will Factor XI Inhibitors Replace Current Anticoagulants for Stroke Prevention in Atrial Fibrillation?
Curr Cardiol Rep. 2024 Sep;26(9):911-917. doi: 10.1007/s11886-024-02100-y. Epub 2024 Jul 23.
3
Atrial fibrillation: age at diagnosis, incident cardiovascular events, and mortality.
Eur Heart J. 2024 Jun 28;45(24):2119-2129. doi: 10.1093/eurheartj/ehae216.
4
When Direct Oral Anticoagulants Should Not Be Standard Treatment: JACC State-of-the-Art Review.
J Am Coll Cardiol. 2024 Jan 23;83(3):444-465. doi: 10.1016/j.jacc.2023.10.038.
5
A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction.
Circulation. 2022 Oct 18;146(16):1196-1206. doi: 10.1161/CIRCULATIONAHA.122.061612. Epub 2022 Aug 27.
6
Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.
Lancet. 2022 Apr 9;399(10333):1383-1390. doi: 10.1016/S0140-6736(22)00456-1. Epub 2022 Apr 3.
7
Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex.
Circulation. 2022 Jan 25;145(4):242-255. doi: 10.1161/CIRCULATIONAHA.121.056355. Epub 2022 Jan 5.
8
Mortality in Patients With Atrial Fibrillation Receiving Nonrecommended Doses of Direct Oral Anticoagulants.
J Am Coll Cardiol. 2020 Sep 22;76(12):1425-1436. doi: 10.1016/j.jacc.2020.07.045.
9
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.
J Am Coll Cardiol. 2019 Jul 9;74(1):104-132. doi: 10.1016/j.jacc.2019.01.011. Epub 2019 Jan 28.
10
Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry.
Circulation. 2014 Apr 15;129(15):1568-76. doi: 10.1161/CIRCULATIONAHA.113.005451. Epub 2014 Jan 24.
Zotero 插件